Table 1 The studies supporting the involvement of miR-93 in cancer malignancy
From: Flaming the fight against cancer cells: the role of microRNA-93
In vitro/in vivo | Effect on cancer | Major results | Refs. |
|---|---|---|---|
Glioblastoma cells | Oncogenesis | MiR-93 enhances the malignancy and proliferation of glioblastoma cells by inhibition of autophagy via down-regulation of Beclin-1, ATG5, and ATG4B | [106] |
EC cells | Oncogenesis | Reducing the capability of radiotherapy by inhibition of BTG3 | [125] |
HeLa and C‐33A cells cervical cancer tissues | Oncogenesis | LncRNA ZNF667 suppresses the invasion and malignancy of cancer cells by inhibition of miR-93-3p | [311] |
Cisplatin-resistant A2780/DDP cell line | Oncogenesis | Inhibition of miR-93 by l-tetrahydropalmatine is beneficial in sensitizing of cancer cells to cisplatin-mediated apoptosis | [312] |
Bladder cancer tissues and cells | Oncogenesis | Upregulation of miR-93 is related to the tumor stage and node stage via stimulation of PEDF | [313] |
Cervical cancer and matched non-cancerous tissue samples | Oncogenesis | Overexpression of miR-93 and inhibition of CDKN1A is associated with poor prognosis of patients | [314] |
Gastric cancer cells | Oncogenesis | By inhibition of TIMP2, miR-93 enhances the malignancy of gastric cancer cells | [315] |
Primary colon cancer cells | Oncogenesis | By inhibition of miR-93, lncRNA LINC01567 reduces the proliferation an malignancy of cancer cells | [316] |
Endometrial carcinoma tissues endometrial carcinoma cell lines HEC-1B and Ishikawa | Oncogenesis | Enhancing the proliferation and malignancy of tumor cells by stimulation of EMT | [317] |
Ovarian carcinoma cell lines OVCAR3, SKOV3/DDP, and HO8910-PM | Oncogenesis | MiR-93-5p down-regulates the expression of RhoC to elevate the invasiveness of cancer cells | [318] |
Human colon cancer tissue and colorectal carcinoma cell lines | Oncosuppressor | Diminishing the malignancy and migration of cancer cells by inhibition of Wnt signaling pathway | [319] |
Hep-2 cells cancer tissues | Oncogenesis | MiR-93 binds to the 3/-UTR of cyclin G2 to inhibit its expression resulting in promoted proliferation of cancer cells | [320] |
Breast cancer tissues | Oncogenesis | Overexpression of miR-93 occurs in triple negative breast cancer | [321] |
Rat model of mammary carcinogenesis | Oncogenesis | Upregulated miR-93 suppresses the expression of Nrf2 to enhance the tumorigenesis of breast cancer cells | [322] |
Tumoral and nontumoral colon tissues | Oncosuppressor | A decrease occurs in the expression of miR-93 in colon cancer cells | [323] |
Early (recurrence within 12 months after surgery) and non-early relapse CRC patients CRC cells | Oncosuppressor | Reducing the progression and growth of cancer cells down-regulation of VEGF, p21 and ERBB2 | [324] |
Cisplatin-resistant ovarian cancer cells | Oncosuppressor | Upregulation of miR-93 reduces the expression of PTEN to stimulate Akt signaling pathway leading to the sensitization of cancer cells to chemotherapy | [325] |